NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics Inc.

An announcement from Journeo ( ($GB:JNEO) ) is now available. Journeo plc has secured £2.4 million of contracts under its four‑year framework agree...

Journeo wins £2.4m UK utility contracts for high‑security infrastructure protection

Neogen ( ($NEOG) ) has provided an update. On March 30, 2026, Neogen Corporation announced that its Chief Legal and Administrative Officer, Amy Roc...

Neogen Announces Departure of Chief Legal Officer Rocklin

An announcement from NeoVolta ( ($NEOV) ) is now available. On March 27, 2026, NeoVolta, Inc. entered into a Sales Agreement with Needham & Company...

NeoVolta Launches $30 Million At-The-Market Stock Offering

ATB Cormark Capital Markets analyst Nicholas Boychuk maintained a Buy rating on Neo Performance Materials Inc on March 20 and set a price target of...

ATB Cormark Capital Markets Reaffirms Their Buy Rating on Neo Performance Materials Inc (NEO)

Neola Medical AB ($SE:NEOLA) announced an update on their ongoing clinical study. The clinical pilot study “Clinical Pilot Study to Assess Safety a...

Neola Medical’s Neonatal Lung Monitor Clears Key Pilot Milestone

INEO Tech Corp. ( ($TSE:INEO) ) has issued an update. INEO Tech Corp. has corrected the location of its March 27, 2026 annual general meeting of sh...

INEO Tech Corrects Venue for March 27 Shareholder Meeting

INEO Tech Corp. ( ($TSE:INEO) ) has issued an update. INEO Tech Corp. will participate in the 38th Annual Roth Conference in Dana Point, California...

Market Cap	$1.10B	P/E Ratio	N/A
52W High	$13.74	52W Low	$4.72
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-106.9%	52W Position	35.7%
Overall Score	48	Value Score	60
Quality Score	44	Technical Score	41

EPS Current Est	$-0.16	EPS Next Est	$-0.02
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NEO	$7.94	-3.41%	1.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NEO	$7.94	-3.4%	1.13M
3
4
5
6

NEO

NEO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NeoGenomics Inc. Data in Excel

Get NeoGenomics Inc. Data in Excel